Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma

August 6th 2020

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma

August 6th 2020

Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.

Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma

August 6th 2020

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma

August 6th 2020

The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Dr. Raje on Remaining Questions in Multiple Myeloma

August 5th 2020

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma Trial

August 4th 2020

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Usmani on Key Findings From the SWOG 1211 Trial in High-Risk Multiple Myeloma

August 3rd 2020

Saad Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

Subcutaneous Daratumumab/Pomalidomide Triplet Improves PFS in Relapsed/Refractory Myeloma

August 3rd 2020

Subcutaneous daratumumab in combination with pomalidomide and dexamethasone showed an improvement in progression-free survival versus pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

FDA Approval Sought for Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

July 29th 2020

A biologics license application has been submitted to the FDA for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Dr. Raje on the Effectiveness of Quadruplet Therapies in Multiple Myeloma

July 29th 2020

Noopur S. Raje, MD, discusses the quadruplet therapies that are currently available for patients with multiple myeloma.

Genetic Abnormalities in Smoldering Myeloma Could Indicate Higher Risk of Disease Progression

July 25th 2020

Patients with smoldering myeloma whose disease harbors select genetic abnormalities may be an indicator that they could be at a higher risk for developing multiple myeloma.

Belantamab Mafodotin Granted Positive EU Opinion for Myeloma

July 24th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for belantamab mafodotin as a monotherapy in the treatment of adult patients with multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and aCD38-directed monoclonal antibody.

Selinexor Triplet Shows Strong Clinical Activity in Relapsed/Refractory Myeloma

July 24th 2020

A triplet regimen comprised of selinexor, daratumumab, and dexamethasone proved to be highly active, inducing deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Raje Relays Recent Developments in Multiple Myeloma

July 21st 2020

Noopur S. Raje, MD, discusses some of the most noteworthy research presented at the 2020 ASCO Virtual Scientific Program and the 2020 European Hematology Association Congress in multiple myeloma.

MMRF CureCloud® Aims to Accelerate Precision Medicine With Real-World Data in Myeloma

July 21st 2020

The Multiple Myeloma Research Foundation CureCloud® is a first-of-its-kind research initiative, developed to help arm researchers with the information they need to accelerate development of novel therapeutic strategies, provide a precision medicine approach to help inform providers’ and patients’ treatment decisions, and ultimately, find a cure for multiple myeloma.

Dr. Costello on Sequencing Challenges in Multiple Myeloma

July 20th 2020

Caitlin Costello, MD, discusses sequencing challenges in multiple myeloma.

FDA Approval Sought for Selinexor in Myeloma After 1 Prior Line of Therapy

July 20th 2020

The FDA has accepted a supplemental new drug application seeking approval for selinexor for the treatment of patients with multiple myeloma following at least 1 previous line of therapy.

Dr. Kumar on the Rationale for the ENDURANCE Trial in Multiple Myeloma

July 17th 2020

Shaji K. Kumar, MD, discusses the rationale for conducting the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020